Revenue

Organon·Products & Services·32 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Nexplanon/Implanon NXT	$242M	$243M	$259M	$248M	$240M	$223M	$210M	$201M
Zetia	$75M	$81M	$77M	$85M	$74M	$93M	$90M	$87M
Other	$72M	$84M	$87M	$78M	$87M	$88M	$85M	$87M
Atozet	$140M	$125M	$77M	$77M	$86M	$95M	$67M	$85M
Other Non-Opiod Pain, Bone and Dermatology	$78M	$74M	$68M	$68M	$80M	$80M	$72M	$68M
Hadlima	$28M	$40M	$44M	$47M	$50M	$63M	$69M	$67M
Nasonex	$60M	$63M	$76M	$72M	$66M	$60M	$65M	$65M
Follistim AQ	$62M	$63M	$66M	$69M	$74M	$64M	$58M	$61M
Arcoxia	$68M	$69M	$59M	$62M	$63M	$71M	$70M	$59M
Renflexis	$69M	$72M	$64M	$57M	$63M	$70M	$61M	$57M
Cozaar/Hyzaar	$60M	$59M	$57M	$55M	$56M	$55M	$53M	$57M
Emgality	$30M	$29M	$38M	$32M	$42M	$51M	$49M	$54M
Other Women's Health	$34M	$40M	$39M	$43M	$42M	$43M	$46M	$46M
Singulair	$93M	$85M	$84M	$74M	$66M	$53M	$59M	$40M
Dulera	$47M	$48M	$52M	$43M	$41M	$34M	$35M	$35M
Diprospan	$37M	$37M	$37M	$30M	$41M	$41M	$38M	$35M
Clarinex	$35M	$27M	$27M	$34M	$34M	$25M	$30M	$31M
Propecia	$28M	$28M	$32M	$26M	$32M	$33M	$28M	$30M
Fosamax	$35M	$38M	$39M	$33M	$34M	$40M	$36M	$29M
Other Cardiovascular	$32M	$29M	$34M	$30M	$34M	$33M	$28M	$28M
Ganirelix Acetate Injection	$27M	$26M	$27M	$27M	$27M	$22M	$24M	$26M
Marvelon/Mercilon	$41M	$29M	$31M	$39M	$33M	$31M	$24M	$26M
Proscar	$23M	$23M	$22M	$24M	$22M	$27M	$24M	$26M
Vtama	—	—	—	$24M	$31M	$34M	$39M	$25M
NuvaRing	$29M	$23M	$25M	$22M	$28M	$26M	$16M	$24M
Other Biosimilars	—	$7M	$6M	$5M	$8M	$9M	$11M	$24M
Vytorin	$28M	$26M	$26M	$23M	$27M	$25M	$25M	$21M
Brenzys	$12M	$27M	$14M	$14M	$22M	$23M	$21M	$20M
Other Respiratory	$13M	$14M	$18M	$13M	$14M	$12M	$12M	$12M
Rosuzet	$9M	$11M	$13M	$4M	$6M	$6M	$8M	$6M
Jada	$14M	$16M	$18M	$15M	$18M	$20M	$20M	$5M
Ontruzant	$48M	$20M	$34M	$18M	$31M	$31M	$19M	$5M
Total	$1.61B	$1.58B	$1.59B	$1.51B	$1.59B	$1.6B	$1.51B	$1.46B